Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

To the Editor: In the report of the recent European controlled trial of inhaled pentamidine for prophylaxis against Pneumocystis carinii pneumonia (PCP), Hirschel and colleagues (April 18 issue)1 state that it appears that prophylaxis against PCP may be less expensive than treating this disease. On the basis of data from the United States, there are several reasons why inhaled pentamidine is unlikely to reduce costs in this country. First, its cost is $100 to $129 per 300-mg vial (the lowest wholesale cost to the hospital), four times the cost in Europe.2,3 In addition, according to data from the Multi-center AIDS. © 1991, Massachusetts Medical Society. All rights reserved.

Original publication




Journal article


New England Journal of Medicine

Publication Date





735 - 737